Potential benefits of intermittent bisphosphonate therapy in osteoporosis

Joint Bone Spine

Volumn 71, Issue 1, 2004, Pages 2-3

  Daragon, Alain ^a,b,c   Pouplin, Sophie ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

Author keywords

Bisphosphonates; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; ETIDRONIC ACID; FLUORIDE; GLUCOCORTICOID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE DENSITY; BONE DESTRUCTION; BONE MINERAL; BONE REMODELING; BONE TURNOVER; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EDITORIAL; ESOPHAGITIS; ESTROGEN THERAPY; FLU LIKE SYNDROME; GASTROESOPHAGEAL REFLUX; HUMAN; NEPHROTOXICITY; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT POSITIONING; POSTMENOPAUSE OSTEOPOROSIS; SENILE OSTEOPOROSIS; SLOW DRUG RELEASE; TREATMENT OUTCOME;

EID: 0842288760     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1297-319X(03)00156-8     Document Type: Editorial

References (12)

1. de Groen P.C., Lubbe D.F., Hirsch L.J., Daifotis A., Stepenson W., Freedholm D., et al. Esophagitis associated with use of alendronate. N Engl J M. 335:1996;1016-1021.
2. Greenspan S.L., Bone H.G., Schnitzer T.J., Watts N.B., Adami S., Foldes A.J., et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. 17:2002;1988-1996.
3. Brown J.P., Kendler D.L., McKlung M.R., Emkey R.D., Adachi J.D., Bolognese M.A., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 71:2002;103-111.
4. Filipponi P., Pedetti M., Fedeli L., Cini L., Palumbo R., Boldrini S., et al. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res. 10:1995;697-703.
5. Vasikaran S.D., Khan S., McCloskey E.V., Kanis J.A. Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone. 17:1995;517-520.
6. Thiébaud D., Burckhardt P., Melchior J., Eckert P., Jacquet A.F., Schnyder P., et al. Two years'effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporosis Int. 4:1994;76-83.
7. Noord R.M., Minkowitz R., Maid P., Lane J.M. Effect of pamidronate and alendronate on bone mineral density in osteoporotic patients. A control matched study [abstract]. J Bone Miner Res. 17:(Suppl 1):2002;S473.
8. Lamy O., Pache I., Fatio S., Sandini L., Krieg M.A., Burckhardt P. Effect of various doses of pamidronate with constant yearly dose in women with osteoporosis: a 2-year pilot study [abstract]. Osteoporosis Int. 13:(Suppl 1):2002;S32.
9. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J M. 346:2002;653-661.
10. Thiébaud D., Burckhardt P., Kriegbaum H., Huss H., Mulder H., Juttmann J.R., et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J M. 103:1997;298-307.
11. Recker R.R., Stakkestad J.A., Felsenberg D., Chesnut C.H., Christiansen C., Ettinger M.P., et al. A new treatment paradigm: quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis: results of a 3-year trial [abstract]. Osteoporosis Int. 11:(Suppl 2):2000;S209.
12. Cosman F., Nieves J., Woelfert L., Formica C., Gordon S., Shen V., et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 16:2001;925-931.